Literature DB >> 10192432

The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia.

G Barosi1, A Ambrosetti, C Finelli, A Grossi, P Leoni, N L Liberato, M C Petti, E Pogliani, M Ricetti, S Rupoli, G Visani, S Tura.   

Abstract

The purpose of this work was to develop a definition of myelofibrosis with myeloid metaplasia (MMM) using diagnostic criteria that would remain valid within the set of patients with chronic myeloproliferative disorders or myelodysplastic syndromes. A list of 12 names for the disease and 37 diagnostic criteria were proposed to a Consensus Panel of 12 Italian experts who ranked them in order so as to identify a core set of criteria. The Panel was then asked to score the diagnosis of 46 patient profiles as appropriate or not appropriate for MMM. Using the experts' consensus as the gold standard, the performance of 90 possible definitions of the disease obtained through the core set was evaluated. 'Myelofibrosis with myeloid metaplasia' ranked as the preferred name of the disease. Necessary criteria consisted of 'diffuse bone marrow fibrosis' and 'absence of Philadelphia chromosome or BCR-ABL rearrangement in peripheral blood cells'. The six optional criteria in the core set consisted of: splenomegaly of any grade; anisopoikilocytosis with tear-drop erythrocytes; the presence of circulating immature myeloid cells; the presence of circulating erythroblasts: the presence of clusters of megakaryoblasts and anomalous megakaryocytes in bone marrow sections; myeloid metaplasia. The definition of the disease with the highest final score was as follows: necessary criteria plus any other two criteria when splenomegaly is present or any four when splenomegaly is absent. The use of this definition will help to standardize the conduct and reporting of clinical studies and should help practitioners in clinical practice.

Entities:  

Mesh:

Year:  1999        PMID: 10192432     DOI: 10.1046/j.1365-2141.1999.01262.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  17 in total

1.  Association of plasma adiponectin concentrations with chronic lymphocytic leukemia and myeloproliferative diseases.

Authors:  Ferit Avcu; A Ugur Ural; M Ilker Yilmaz; Necati Bingol; Oral Nevruz; Kayser Caglar
Journal:  Int J Hematol       Date:  2006-04       Impact factor: 2.490

2.  The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms.

Authors:  Damla Olcaydu; Elisa Rumi; Ashot Harutyunyan; Francesco Passamonti; Daniela Pietra; Cristiana Pascutto; Tiina Berg; Roland Jäger; Emma Hammond; Mario Cazzola; Robert Kralovics
Journal:  Haematologica       Date:  2010-12-20       Impact factor: 9.941

3.  Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis.

Authors:  Alessandro M Vannucchi; Alessandro Pancrazzi; Paola Guglielmelli; Simonetta Di Lollo; Costanza Bogani; Gianna Baroni; Lucia Bianchi; Anna Rita Migliaccio; Alberto Bosi; Francesco Paoletti
Journal:  Am J Pathol       Date:  2005-09       Impact factor: 4.307

4.  How I treat essential thrombocythemia.

Authors:  Philip A Beer; Wendy N Erber; Peter J Campbell; Anthony R Green
Journal:  Blood       Date:  2010-11-24       Impact factor: 22.113

5.  Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients.

Authors:  Elisa Rumi; Francesco Passamonti; Chiara Elena; Daniela Pietra; Luca Arcaini; Cesare Astori; Silvia Zibellini; Emanuela Boveri; Cristiana Pascutto; Mario Lazzarino
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

6.  Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms.

Authors:  Philip A Beer; Christina A Ortmann; Frank Stegelmann; Paola Guglielmelli; John T Reilly; Thomas S Larsen; Hans C Hasselbalch; Alessandro M Vannucchi; Peter Möller; Konstanze Döhner; Anthony R Green
Journal:  Haematologica       Date:  2010-09-07       Impact factor: 9.941

7.  Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis.

Authors:  Stefan O Ciurea; Delwin Merchant; Nadim Mahmud; Takefumi Ishii; Yan Zhao; Wenyang Hu; Edward Bruno; Giovanni Barosi; Mingjiang Xu; Ronald Hoffman
Journal:  Blood       Date:  2007-05-01       Impact factor: 22.113

Review 8.  Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).

Authors:  Jan Jacques Michiels; Juergen Thiele
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

9.  Comparison of different criteria for the diagnosis of primary myelofibrosis reveals limited clinical utility for measurement of serum lactate dehydrogenase.

Authors:  Philip A Beer; Peter J Campbell; Anthony R Green
Journal:  Haematologica       Date:  2010-06-09       Impact factor: 9.941

10.  JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.

Authors:  Linda M Scott; Wei Tong; Ross L Levine; Mike A Scott; Philip A Beer; Michael R Stratton; P Andrew Futreal; Wendy N Erber; Mary Frances McMullin; Claire N Harrison; Alan J Warren; D Gary Gilliland; Harvey F Lodish; Anthony R Green
Journal:  N Engl J Med       Date:  2007-02-01       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.